Prognostic Value of Plasma Biomarkers Among Patients With Hypertension

Hypertension Clinical Trial

— BIOMS-HTN  

Official title:

Prognostic Value of Plasma Biomarkers Among Patients With Hypertension

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04107584
• Other study ID #: HTN2019
• Status: Recruiting
• Start date: April 1, 2017
• Est. completion date: August 2022

Study information

• Verified date: September 2019
• Source: Beijing Institute of Heart, Lung and Blood Vessel Diseases
• Contact: Yulin Li, PhD
• Phone: 0086-010-64456453
• Email: lyllyl_1111[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Hypertension is the most important risk factor for cardiovascular and cerebrovascular diseases，and also a substantial public health problem. The purpose of the study is to investigate the association between plasma biomarkers and adverse outcomes in patients with hypertension.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 600
• Est. completion date: August 2022
• Est. primary completion date: August 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• >18 years old

• In accordance with the diagnosis of hypertension (BP=140/90mmHg)

Exclusion Criteria:

• The exclusion Criteria for the study program were as follows:

Pregnancy, history of heart failure or left ventricular ejection fraction less than 40%, myocardial infarction within one month, percutaneous transluminal coronary angioplasty or coronary artery bypass grafting, cerebrovascular disease, severe liver disease, severe chronic renal failure (eGFR less than 30 mL/min/1.73 m2) in the past three months.

Related Conditions & MeSH terms

• Hypertension

Locations

Country	Name	City	State
China	Beijing Anzhen Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Institute of Heart, Lung and Blood Vessel Diseases

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary mortality of hypertension	The incidence rate of primary mortality of hypertension	Through study completion, an average of 2 years
Secondary	Secondary outcomes of heart	The incidence rate of left ventricular hypertrophy, myocardial infarction, congestive heart failure, and arrhythmia	Through study completion, an average of 2 years
Secondary	Secondary outcomes of brain	The incidence rate of stroke (include cerebral hemorrhage and cerebral ischemia	Through study completion, an average of 2 years
Secondary	Secondary outcomes of kidney	The incidence rate of hypertensive renal injure and end-stage renal disease	Through study completion, an average of 2 years
Secondary	Secondary outcomes of eyes	The incidence rate of hypertensive eye injure	Through study completion, an average of 2 years